RWA Wealth Partners LLC Boosts Holdings in Bristol Myers Squibb Company $BMY

RWA Wealth Partners LLC boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 27.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 72,161 shares of the biopharmaceutical company’s stock after purchasing an additional 15,454 shares during the quarter. RWA Wealth Partners LLC’s holdings in Bristol Myers Squibb were worth $3,340,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of BMY. Wellington Management Group LLP grew its holdings in shares of Bristol Myers Squibb by 297.0% during the first quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company’s stock valued at $1,447,198,000 after buying an additional 17,750,938 shares during the last quarter. GQG Partners LLC lifted its position in Bristol Myers Squibb by 22,647.6% in the 1st quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company’s stock valued at $733,310,000 after acquiring an additional 11,970,598 shares in the last quarter. Nuveen LLC purchased a new stake in Bristol Myers Squibb during the 1st quarter valued at $624,369,000. Kingstone Capital Partners Texas LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth $98,898,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Bristol Myers Squibb by 17.7% in the first quarter. Goldman Sachs Group Inc. now owns 14,051,319 shares of the biopharmaceutical company’s stock worth $856,990,000 after purchasing an additional 2,117,249 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Stock Performance

BMY opened at $46.74 on Friday. The company’s 50 day moving average is $45.25 and its 200 day moving average is $46.69. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The company has a market cap of $95.14 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 2.23 and a beta of 0.33. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period last year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, equities research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Friday, October 3rd were given a dividend of $0.62 per share. The ex-dividend date was Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.3%. Bristol Myers Squibb’s payout ratio is 83.78%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BMY shares. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Finally, Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fifteen have issued a Hold rating to the company. According to MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average price target of $57.23.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.